Thursday, October 29, 2020

Anticholinergic Drugs Increase Risk of Cognitive Decline

A new study finds that anticholinergic drugs, like antidepressants and antipsychotics, are associated with mild cognitive decline.
antipsychotic drugs

Antipsychotic Augmentation Increases Risk of Death

A new study finds that adding an antipsychotic to existing antidepressant treatment is associated with a 45% increased risk of early death.

Greater Exposure to Antipsychotics Associated with Worse Long-Term Outcomes

A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.

Very Slow Taper Best for Antipsychotic Discontinuation

An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.

An FDA Whistleblower’s Documents: Commerce, Corruption, and Death

In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

Antipsychotics Associated with Severe COVID-19 and Fatal Outcomes

A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.

For People “At Risk for Psychosis,” Antipsychotics Associated with Worse Outcomes

Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.

Randomized Controlled Trial Confirms That Antipsychotics Damage the Brain

A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.

Do Antipsychotics Protect Against Early Death? A Review of the Evidence

Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.

Antipsychotic Trials Show Increasing Placebo Response and Declining Drug Response

A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.

Does Longer Duration of Untreated Psychosis Cause Worse Outcomes?

New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.

Largest Survey of Antipsychotic Experiences Reveals Negative Results

A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.

Review Explores First-Person Experiences of People Taking Antipsychotics

A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.

The Charade of New Drug Approvals for Schizophrenia

The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

Relapse in Antipsychotic Drug Trials is Poorly Defined

There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.
digital antipsychotic

The Rise of the Digital Asylum

The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

How Do We Test the Effects of Long-Term Exposure to Antipsychotics?

A new attempt to study the neurological effects of long-term exposure to antipsychotics uses healthy volunteers on minimal doses for 15 days.

How Exercise Can Help With First Episode Psychosis

New study examines the experiences of people utilizing an exercise program following a first-episode psychosis.

Review Finds FDA Approval of Digital Antipsychotic Misguided

The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.
A box of Zyprexa pills.

Lack of Clear Guidelines Prevent Clinicians from Reducing Antipsychotics

A recently published study from noted critical psychiatry expert Joanna Moncrieff explored the barriers that prevent clinicians from helping service users in discontinuing or...
Yellow sign reading "Cognitive Hazard"

Discontinuation of Antipsychotics Improves Cognitive Functioning

A study, recently published in Psychological Medicine, examined the cognitive functioning of individuals with schizophrenia who discontinued antipsychotics, and those who maintained their antipsychotic...

Anticholinergic Psychiatric Drugs Linked to a 50% Increase in Dementia

People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.

Service-Users See Long-Term Antipsychotic Use as Compromising Recovery, Review Finds

A new meta-review examines the experiences of antipsychotic drugs use among people diagnosed with a psychotic disorder.

Better Outcomes Off Medication for Those Recovered from First-Episode Schizophrenia

A new study has found that of 10 people who were fully recovered from their first episode of schizophrenia (FES), those not taking antipsychotics did better in terms of cognitive, social, and role functioning—and reached full recovery more quickly.

Antipsychotics Associated with High Risk of Death in Children

A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.

Follow Us

19,639FansLike
11,994FollowersFollow
4,730SubscribersSubscribe